LIDE’s CRO foundation is in traditional in-vivo studies, providing standard in-vivo efficacy platforms like CDX and PDX. Years of innovation and a penchant for using the latest technologies has resulted in novel LIDE offerings also.
|PDX – Patient Derived Xenograft||Gold standard for IND filing – 89% correlation with clinical response||Over 1600 LIDE PDX models, many with rare gene alterations or drug resistance|
|MiniPDX®||Novel, more cost-effective alternative to PDX with faster turnaround time, but still well correlated with PDX results and clinical response||LIDE has optimized its MiniPDX® technologies for years, with several supporting papers and currently running a RWE study in China|
|CDX – Cell-line Derived Xenograft||Traditional pre-cursor to PDX – only 5% correlation with clinical response||Over 50 LIDE CDX models,|
|CRC – Conditionally Reprogrammed Cells||Novel alternative to commercialized cell lines to maintain heterogeneity, to increase correlation with clinical results||LIDE has years of experience working with CRCs to expand cell cultures from patient tissue samples for in-vivo studies|
LIDE’s Functional Diagnosis platform offers drug companies a more efficient pathway to successful clinical trials.
LIDE’s IO platform leverages HuPBMC reconstituted or co-inoculated (with commercialized cell line or PDX cell suspension) models established from CDXs or PDXs.
Fig. New, optimized R&D roadmap using LIDE Functional Diagnosis platform